Tonix Pharmaceuticals reported second-quarter 2026 net sales of approximately $11 million for TONMYA, its fibromyalgia treatment, representing a 197% increase quarter-over-quarter. The acceleration follows the drug’s November 2025 commercial launch and reflects expanding payer coverage that now reaches approximately 136 million covered lives, or 43% of total U.S. lives. The company did not provide forward guidance for the current quarter or full year.
Total prescriptions for TONMYA reached 12,592 in the second quarter, up 100% from the prior quarter, though this figure includes bridge prescriptions that do not immediately generate revenue. New patient prescriptions increased 36% quarter-over-quarter, while refills surged 207% in the same period. The company announced in May and June 2026 commercial payer agreements with two leading group purchasing organizations covering approximately 52 million lives, or 29% of commercial lives in the U.S. Medicaid coverage now extends to approximately 75 million lives across most states. A managed Medicare payer agreement is scheduled to take effect January 1, 2027, adding approximately nine million Medicare lives and bringing total coverage to approximately 145 million lives, or 46% of the approximately 314 million covered lives in the U.S.
What it means
The 197% quarter-over-quarter revenue growth reflects two distinct drivers: the base effect of launching from near-zero in the prior quarter, and the operational reality of payer coverage expansion translating into patient access. The refill rate of 207% growth is the more telling metric here, since refills indicate patients already on therapy rather than initial fills or bridge prescriptions awaiting coverage determinations. That refills are accelerating faster than new patient prescriptions (36% growth) suggests the drug is retaining patients once they begin treatment, a prerequisite for sustained revenue growth in a chronic indication like fibromyalgia.
The payer coverage milestone, reaching 43% of U.S. lives by mid-year, is material because fibromyalgia treatment historically faces access barriers through prior authorization and formulary restrictions. Tonix’s achievement of coverage across commercial, Medicare, and Medicaid channels within nine months of launch is operationally significant and reduces the risk that revenue growth will plateau due to access constraints. The company is also deploying 50 additional sales representatives by September 2026, bringing the total sales force to approximately 150 people, which suggests management expects the coverage gains to translate into prescriber reach.
The open question the filing leaves unresolved is whether the 197% quarter-over-quarter growth rate can persist as the base grows. The company provided no guidance on Q3 or full-year 2026 revenue, making it impossible to assess whether management expects the acceleration to continue, stabilize, or decelerate. The bridge prescription component of the 12,592 total prescriptions is also undisclosed in magnitude, which obscures the true underlying demand signal. If bridge prescriptions represent a material share of the total, the revenue growth rate may overstate the sustainable prescription rate once coverage determinations are resolved.
What to watch
The next disclosure point will be third-quarter 2026 results, expected in November 2026, which will reveal whether the 197% growth rate persists after the September sales force expansion and whether the January 2027 Medicare coverage expansion has begun to materialize in the fourth quarter. Any guidance provided at that time will clarify management’s view of the drug’s trajectory and the sustainability of current growth rates.
Source: the company’s 8-K filed 2026-08-10 with the SEC.
